案例报告:Atezolizumab和bevacizumab用于结合的肝细胞-胆管癌
Tomoyuki Satake1, Taro Shibuki1, Kazuo Watanabe1
1Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Frontiers in oncology
|August 7, 2023
概括
结合性肝细胞胆管癌 (cHCC-CCA) 的治疗选择有限. 阿特佐利祖马布加贝瓦齐祖马布在6例无法切除的cHCC-CCA病例中显示出有前途的结果,观察到部分反应.
科学领域:
- 肝胆道癌症 肝胆道癌症
- 胃肠病学 胃肠病学
- 医学瘤学 医学瘤学
背景情况:
- 结合性肝细胞胆管癌 (cHCC-CCA) 是一种罕见的初级肝癌.
- 对于cHCC-CCA存在有限的治疗策略,特别是对于无法切除的病例.
- 对于不可切除的cHCC-CCA,没有标准的全身治疗方法.
研究的目的:
- 评估阿特佐利祖马布加贝瓦齐祖马布在无法切除的cHCC-CCA.患者中的疗效和安全性.
- 介绍一种罕见的肝癌亚型的新型治疗方法的病例系列数据.
主要方法:
- 六名患有无法切除的cHCC-CCA.的患者的回顾性病例系列.
- 进行的治疗:阿特佐利祖马布加贝瓦西祖马布.
- 评估治疗反应和不良事件.
主要成果:
- 观察到三个部分反应 (PR) 和一个稳定疾病 (SD) 是最佳反应.
- 两名患者继续治疗至少五个月.
- 两名患者因不良事件而停止治疗.
结论:
- 阿特佐利祖马布加贝瓦齐祖马布显示出作为治疗不可切割的cHCC-CCA的有效治疗的潜力.
- 需要进一步的研究,以在更大的队列中证实这些发现.
- 对不良事件的管理对于治疗的延续至关重要.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.